Loading…
Each decision rolls up every audited claim behind one longevity question — what each creator said, how it stacks up against the literature, and the verdict.
For most symptomatic perimenopausal women under 60: yes. WHI re-analyses are clear; the 2002 fear was overcorrected.
For symptomatic hypogonadal men: yes. For low-normal asymptomatic men: the case is much weaker.
Reliable hormonal effect, unreliable healthspan effect. Adrenal-suppression risk is under-discussed.
For subclinical hypothyroid with symptoms: defensible. For asymptomatic optimization: outpaces the evidence.